Lorlatinib price after medical insurance reimbursement in 2023

Lorlatinib (Lorlatinib) is an innovative drug mainly used to treat specific types of cancer, especially one of non-small cell lung cancer (NSCLC). It is administered through the oral route and is rapidly absorbed, usually reaching peak concentrations within hours. Lorlatinib has been marketed in China and has been included in medical insurance. Reimbursement is limited to patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. For specific patients, please consult the local medical insurance bureau or hospital.